Episode Details
Back to EpisodesCan an oral diabetes drug reduce hepatic scarring from MASH?
Episode 519
Published 1 year, 4 months ago
Description
A Chinese trial found dapagliflozin improved MASH outcomes, with higher resolution and fibrosis improvement rates than placebo. A JAMA Network Open survey showed 42% of abortion providers in ban states relocated, mostly to states with protections, highlighting growing care gaps. An oncology study found AI analysis of body composition better predicted chemo dose reductions than body surface area, especially in women.